WEBThe investigational medicinal product dossier ( IMPD) should be provided in a clearly structured format following the CTD format of Module 3 and include the most up-to-date available information relevant to the clinical trial at time of …
Investigational Medicinal Product Dossier (IMPD)
WEBAn Investigational Medicinal Product Dossier (IMPD) contains data on the quality, production and control of the medicinal product being researched. The IMPD consists of 2 parts: The Quality section with information on the active medicinal product, placebo and reference medicine (if applicable).
WEBFor drug substances or IMPs to be used in clinical trials as described in chapters 2 to 8, reference to either the European Pharmacopoeia (Ph. Eur.), the Pharmacopoeia of an EU Member State, the United States Pharmacopoeia (USP) or the Japanese Pharmacopoeia (JP) is acceptable.
WEBWhen preparing an IMPD to include in CTAs that will be submitted to competent authorities in EU member states it is important to be aware of applicable EMA guidance documents and Ph Eur monographs to avoid potential GNAs during review of the CTA. From the information The CMC section of an EU IMPD: Considerations for US sponsors Author
WEBFor drug substances or IMPs to be used in clinical trials as described in chapters 2 to 8, reference to either the European Pharmacopoeia (Ph. Eur.), the Pharmacopoeia of an EU Member State, the United States Pharmacopoeia (USP) or the Japanese Pharmacopoeia (JP) is acceptable.
WEB<DATE> QUALITY. AUTHORS. Explanatory text: Depending on the nature of the IMP one of the following EU guidelines on quality documentation for clinical trial applications is applicable as expressed in the scope-section of each guideline:
WEBauthorisation in the IMP Dossier (IMPD). This guideline addresses the specific documentation requirements on the biological, chemical and pharmaceutical quality of IMP containing biological / biotechnology derived substances in cases where no 'simplified IMPD' is submitted (see section 2.7.3. of the detailed guidance CT-1).
What is an IMPD? | Freyr - Global Regulatory Solutions and …
WEBThe IMPD is divided into four sections which summarizes the relevant information on quality, pre-clinical, clinical studies, including critical analyses of the non-clinical and clinical data related to the possible risks and benefits of the proposed study, as well as any available previously generated human data and an assessment of the overall ...
Investigational Medicinal Product Dossier (IMPD)
WEBThe Investigational Medicinal Product Dossier is a document divided in four distinct sections. It provides information on (i) the quality, manufacture and control of the IMP, (ii) the non-clinical studies conducted with the IMP, (iii) the clinical use of the IMP, and (iv) the overall risk / benefit assessment of the IMP in the proposed trial.
New IMPD Guideline on the Requirements for Quality …
WEBJun 6, 2012 · The new IMPD Guideline - which has been recently published by the EMA - describes the requirements for quality documentation concerning biotechnological investigational medicinal products and provides - among other things - statements about shelf-life extension. Get more here.
- Some results have been removed
Skip to content